Coll et al. (2015) found that a small-molecule inhibitor, MCC950, showed its potential as a therapeutic drug in many NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases. The gene discussed is NLRP3; the disease is autoimmune disease.